Results 251 to 260 of about 3,727,606 (394)

The Latin American Front [PDF]

Thought, 1946
openaire   +2 more sources

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high‐, middle‐ and low‐income countries – A Global Congestive Heart Failure (G‐CHF) study

European Journal of Heart Failure, EarlyView.
Abstract Aims The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels. Methods and results We enrolled 17 321 participants with HF from 40 countries.
Darryl P. Leong, Philip G. Joseph, Hisham Dokainish, Stefan Störk, John V.V. McMurray, Lisa M. Mielniczuk, Sanjib Kumar Sharma, Andrés Orlandini, Kamilu M. Karaye, Antoni Bayes‐Genis, Tara McCready, Alex Grinvalds, Kumar Balasubramanian, Kelley R. Branch, Kristian Kragholm, Salim Yusuf, on behalf of the G‐CHF Investigators   +16 more
wiley   +1 more source

Is the present cut-point to define type 2 diabetes appropriate in Latin-Americans? [PDF]

World J Diabetes, 2014
López-Jaramillo P, Velandia-Carrillo C, Gómez-Arbeláez D, Aldana-Campos M.   +3 more
europepmc   +1 more source

Oil Laws of Latin America [PDF]

, 1923
Edward James Schuster, Frank Feuille
openalex   +1 more source

End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)

European Journal of Heart Failure, EarlyView.
End‐organ protective effect of serelaxin in patients with acute heart failure. CV, cardiovascular; HF, heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide. Abstract Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy.
Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry H. Greenberg, Gadi Cotter, Beth A. Davison, Iris E. Beldhuis, G. Michael Felker, Gerasimos Filippatos, Peter S. Pang, Piotr Ponikowski, Claudio Gimpelewicz, John R. Teerlink   +12 more
wiley   +1 more source

Melasma in Latin America: options for therapy and treatment algorithm

Journal of the European Academy of Dermatology and Venereology, 2009
T. Cestari, I. Arellano, D. Hexsel, Ortonne Jp   +3 more
semanticscholar   +1 more source

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

European Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga, Faiez Zannad, Ciaran J. McMullan, Aiwen Xing, Davis Gates, Kevin J. Anstrom, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Yogesh N.V. Reddy, Giuseppe M.C. Rosano, Michele Senni, James Udelson, Adriaan A. Voors, Javed Butler   +21 more
wiley   +1 more source

Birth Outcomes of Latin Americans in Two Countries with Contrasting Immigration Admission Policies: Canada and Spain. [PDF]

PLoS One, 2015
Urquia ML, Vang ZM, Bolumar F.
europepmc   +1 more source

Distribution of the Handbook of Latin American Studies: 1938 [PDF]

, 1940

openalex   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source